Evidence map›Paper›PMID 36139140›Full record

ArticleBiomolecules2022

The Association of Metformin, Other Antidiabetic Medications and Statins on the Prognosis of Rectal Cancer in Patients with Type 2 Diabetes: A Retrospective Cohort Study.

Sami Erkinantti, Ari Hautakoski, Reijo Sund, Martti Arffman, Elina Urpilainen, Ulla Puistola, Esa Läärä, Arja Jukkola, Peeter Karihtala

Full text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sami ErkinanttiMedical Research Center Oulu, Oulu University Hospital and University of Oulu, P.O. Box 8000, 90014 Oulu, Finland.ORCID 0000-0003-2538-2941
Ari HautakoskiMedical Research Center Oulu, Oulu University Hospital and University of Oulu, P.O. Box 8000, 90014 Oulu, Finland.
Reijo SundInstitute of Clinical Medicine, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland.ORCID 0000-0002-6268-8117
Martti ArffmanDepartment of Public Health and Welfare Finnish Institute for Health and Welfare, P.O. Box 30, 00271 Helsinki, Finland.ORCID 0000-0002-1647-4783
Elina UrpilainenMedical Research Center Oulu, Oulu University Hospital and University of Oulu, P.O. Box 8000, 90014 Oulu, Finland.
Ulla PuistolaMedical Research Center Oulu, Oulu University Hospital and University of Oulu, P.O. Box 8000, 90014 Oulu, Finland.
Esa LääräResearch Unit of Mathematical Sciences, University of Oulu, P.O. Box 3000, 90014 Oulu, Finland.
Arja JukkolaDepartment of Oncology and Radiotherapy, Tampere University Hospital, Cancer Center Tampere, Faculty of Medicine and Health Technology, Tampere University, P.O. Box 2000, 33521 Tampere, Finland.
Peeter KarihtalaDepartment of Oncology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, P.O. Box 180, 00029 Helsinki, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metformin and statin use have been associated with an improved prognosis for colorectal cancer in persons with type 2 diabetes (T2D). Data regarding rectal cancer (RC) have been inconclusive; therefore, we investigated the issue with high-quality data and a robust study design. We identified 1271 eligible patients with T2D and incident RC between 1998 and 2011 from the Diabetes in Finland (FinDM) database. Cox models were fitted for cause-specific mortality rates to obtain adjusted estimates of the hazard ratios (HR) with 95% confidence intervals (CI) in relation to use of antidiabetic medication (ADM) and statins before the RC diagnosis and for post-diagnostic use in a time-dependent exposure manner. No sufficient evidence was found for either pre- or post-diagnostic metformin use and RC mortality (HR 0.96, 95% CI 0.67-1.38, and 0.70, 95% CI 0.45-1.10, respectively) when compared to other oral ADMs. Both pre- and post-diagnostic statin use appeared to be inversely associated with mortality from RC (HR 0.77 95% CI 0.63-0.94, and 0.57, 95% CI 0.42-0.78, respectively). Our study was inconclusive as to the association of metformin use with the prognosis of RC, but statin use was found to predict reduced mortality, both from RC and from other causes of death in persons with T2D.

Indexed as

Diabetes Mellitus, Type 2Hydroxymethylglutaryl-CoA Reductase InhibitorsMetforminRectal NeoplasmsHumansHypoglycemic AgentsRetrospective StudiesHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsMetformincancercohortdiabetesinsulinmetforminprognosisrectalstatins

Identifiers

PMID36139140
PMCPMC9496504

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.